Autolus Therapeutics (NASDAQ:AUTL) Announces Quarterly Earnings Results, Meets Estimates

Key Points

• Autolus Therapeutics met analysts’ quarterly EPS estimate at a loss of $0.21 per share and beat revenue expectations, reporting $41.24 million versus $39.54 million expected. Aucatzyl revenue grew 95% year over year, and the company raised its 2026 revenue outlook to at least $150 million.
• Commercial progress and manufacturing efficiency boosted performance: Autolus had authorized 90 U.S. treatment centers, above its 80-center goal, while Q3 gross margin improved to 57%.
• The company reported $248.4 million in cash and expects funding into Q2 2028, assuming projected sales and credit-facility proceeds. Its first BOBCAT progressive-MS data presentation was pushed back to October 2027 for longer follow-up.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.21) EPS for the quarter, hitting analysts' consensus estimates of ($0.21), FiscalAI reports. Autolus Therapeutics had a negative net margin of 238.66% and a negative return on equity of 178.66%. The company had revenue of $41.24 million during the quarter, compared to the consensus estimate of $39.54 million.

Here are the key takeaways from Autolus Therapeutics' conference call:

• AUCATZYL revenue accelerated: Q3 net product revenue rose 95% year over year to $41.2 million, and Autolus now expects full-year 2026 revenue of at least $150 million, above its prior guidance range.
• Commercial reach expanded ahead of plan, with 90 U.S. centers authorized against an 80-center goal and 18 centers authorized in the U.K.; management said the U.K. launch is going well.
• Gross margin improved to 57% in Q3 and 44% year to date. Management attributed the gains to higher production volumes and manufacturing efficiencies, saying the company expects continued gradual improvement.
• Cash, cash equivalents, and marketable securities totaled $248.4 million at quarter-end; the company expects funding into Q2 2028, assuming anticipated AUCATZYL sales and $25 million from the second tranche of its credit facility. Q3 net loss was $55.1 million.
• Autolus moved its first BOBCAT progressive MS data presentation to October 2027 to allow longer follow-up, citing expert feedback that at least 12 months is needed to assess clinical outcomes. Management said the study remains on track, but the data update will come later than previously anticipated.

Autolus Therapeutics Stock Down 7.2%

Shares of AUTL traded down $0.10 during mid-day trading on Tuesday, reaching $1.23. The company's stock had a trading volume of 2,987,475 shares, compared to its average volume of 1,832,511. The company has a debt-to-equity ratio of 1.04, a current ratio of 4.89 and a quick ratio of 4.40. The company's 50 day moving average is $1.78 and its 200 day moving average is $1.66. The stock has a market cap of $326.05 million, a PE ratio of -1.17 and a beta of 2.32. Autolus Therapeutics has a 12-month low of $1.12 and a 12-month high of $2.58.

Analyst Ratings Changes

Several brokerages recently weighed in on AUTL. Weiss Ratings downgraded shares of Autolus Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, November 3rd. Wall Street Zen raised shares of Autolus Therapeutics from a "sell" rating to a "hold" rating in a report on Sunday, August 16th. Finally, HC Wainwright assumed coverage on Autolus Therapeutics in a research report on Monday, November 2nd. They set a "buy" rating for the company. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $10.00.

About Autolus Therapeutics

Autolus Therapeutics plc is a biopharmaceutical company focused on developing and commercializing programmed T-cell therapies for cancer. The company's approach is designed to engineer T cells to recognize and eliminate malignant cells while incorporating features intended to improve activity, persistence and safety.

Its lead product, obecabtagene autoleucel, is an autologous CAR T-cell therapy marketed in the United States under the brand name Aucatzyl. It is used to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.